Riskpilot← Back to searchSign inGet full accessBrunes Pharm Aktiebolag
ABActiveOrg 5564160652FimtaMedical specialists activities · NACE 8622Est. 19910 employees
Revenue 2024
SEK 219K
-25% vs 2023
EBITDA margin
—
Equity ratio
79.8%
Financial strength
Net profit 2024
SEK -2K
-112% vs 2023
| Revenue | SEK 219K | -25% |
| EBITDA | — | — |
| Net profit | SEK -2K | -112% |
| Total assets | SEK 253K | -5% |
| Equity | SEK 202K | -1% |
| Employees | 0 | — |
Legal name
Brunes Pharm Aktiebolag
Org number
5564160652
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
7 januari 1991
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva medicinsk konsultverksamhet samt jord- och skogsbruk med hästuppfödning för tävlingsverksamhet ävensom idka därmed förenlig verksamhet.
Address
Fimta
Phone
+46150660322
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 305 | 316 | 244 | 293 | 219 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 20 | 56 | −65 | 21 | — |
| Depreciation & amort. | −4 | −4 | −4 | −4 | −2 |
| EBIT | 16 | 52 | −69 | 17 | −2 |
| Net financials | — | — | — | — | — |
| Profit before tax | 16 | 52 | −69 | 17 | −2 |
| Tax | −6 | −13 | −0 | −0 | −0 |
| Net profit | 10 | 39 | −69 | 17 | −2 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 364 | 433 | 330 | 266 | 253 |
| Equity | 318 | 357 | 188 | 205 | 202 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 46 | 77 | 142 | 61 | 51 |
| Total debt | 46 | 77 | 142 | 61 | 51 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
79.8%
This company
38.2%
Market median
+109% vs market
20202024
Return on equity
-1.0%
This company
18.4%
Market median
-105% vs market
20202024
Net profit margin
-0.9%
This company
8.1%
Market median
-111% vs market
20202024
Asset turnover
0.87×
This company
1.12×
Market median
+22% vs market
20202024
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HC Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Brunes Pharm Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Christian Brunes | Chief Executive Officer | 0 companies |
| Ingrid Birgitta Brunes | Board of Directors | 0 companies |